



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First-Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: August 14, 2007

Signature: 

(Jeanne M. Brashears)

Docket No.: 28967/57946  
(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Bradley McCall

Application No.: 10/522,232

Confirmation No.: 1644

Filed: July 8, 2005

Art Unit: 1647

For: METHODS AND COMPOSITIONS FOR  
ACTIVATING OR INHIBITING VEGF-D  
AND VEGF-C

Examiner: Christine J. Saoud

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.97, Applicant hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicant has become aware of the following documents, cited in an European Search Report mailed May 15, 2007 and received by the Applicant on May 23, 2007, during the prosecution of European Application No. 03765736.8, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submits these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the European Search Report and of each document required under 37 CFR 1.98(a)(2) cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se*

as a representation that such document is prior art. Moreover, Applicant understands the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

I hereby certify, pursuant to 37 CFR 1.97(e)(1), that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 28967/5794C. A duplicate copy of this paper is enclosed.

Dated: August 14, 2007

Respectfully submitted,

By Jeanne M. Brashears  
Jeanne M. Brashears

Registration No.: 56,301  
MARSHALL, GERSTEIN & BORUN LLP  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300  
Agent for Applicant



Substitute for form 1449/PTO

Used in Lieu of PTO/SB/08A/B  
(Based on PTO 04-07 version)

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	28967/5794C
-------	---	----	---	------------------------	-------------

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A1	5,304,118	04-19-1994	Trese et al.		
A2	4,645,668	02-24-1987	Pinnell		

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number-Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
B1	GB-985,498	03-10-1965	Jensen		✓
B2	WO-00/18436	04-06-2000	Leuven Research & Development		✓
B3	WO-91/11193	08-08-1991	Children's Hospital		✓

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those applications which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. \* Applicant's unique citation designation number (optional). \* See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued document, by the two-letter code (WIPO Standard ST.1). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>2</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
C1	Bell, William R., M.D.; "The Fibrinolytic System in Neoplasia," <i>Seminars in Thrombosis and Hemostasis</i> , Vol. 22 (6), pp. 459-478 (1996).		
C2	Carmeliet, Peter, et al.; "Insights in Vessel Development and Vascular Disorders Using Targeted Inactivation and Transfer of Vascular Endothelial Growth Factor, the Tissue Factor Receptor, and the Plasminogen System," <i>Annals New York Academy of Sciences</i> , pp. 191-206, XP009083100.		
C3	European Search Report for European Application No. 03765736.8; mailed 05/15/07.		
C4	Wang, et al.; "Induction of KDR Expression in Bovine Arterial Endothelial Cells by Thrombin: Involvement of Nitric Oxide," <i>Journal of Cellular Physiology</i> , Vol. 190, pp. 238-250 (2002).		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

Examiner Signature	/Christine Saoud/	Date Considered	01/22/2008
--------------------	-------------------	-----------------	------------



Application No. (if known): 10/522,232

Attorney Docket No.: 28967/5794C

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on August 14, 2007  
Date

Joanne M. Brashier  
Signature

Joanne M. Brashier

Typed or printed name of person signing Certificate

56,301  
Registration Number, if applicable

(312) 474-6657  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (9 References) (1 page)